Combined effects of simvastatin and fibroblast growth factor‑2 on the proliferation and differentiation of preosteoblasts
- Authors:
View Affiliations
Affiliations: Department of Periodontics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 137‑701, Republic of Korea
- Published online on: July 17, 2013 https://doi.org/10.3892/br.2013.137
-
Pages:
812-814
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Simvastatin reportedly promotes osteoblastic and inhibits osteoclastic activity. It increases bone formation when injected subcutaneously over the calvaria in mice. It also increases cancellous bone volume in rats following oral administration. Fibroblast growth factor‑2 (FGF‑2), a member of the FGF family, is expressed by cells of the osteoblastic lineage. FGF‑2 promotes osteoblast proliferation and it is secreted during the healing process of fractures or at bone surgery sites. FGF‑2 reportedly regulates bone formation and osteoblast differentiation. In this study, the combined effects of simvastatin and FGF‑2 on the proliferation and differentiation of preosteoblasts were investigated and an alkaline phosphatase (ALP) activity test was performed to assess the differentiation. Moreover, the expression of proteins associated with bone formation were measured using western blot analysis. The results demonstrated that the protein content of the cultures grown in osteogenic differentiation media in the presence of FGF‑2 at a concentration of 20 ng/ml was higher compared to that of the untreated control cultures. ALP activity was decreased when cells were treated with FGF‑2 (2 and 20 ng̸ml) and increased when cells were treated with simvastatin. The cultures grown in the presence of 1 µM of simvastatin and 2 ng̸ml of FGF‑2 exhibited increased ALP activity when compared to that in the 2 ng̸ml FGF‑2‑only group. The combination of 1.0 µM simvastatin and 2 ng̸ml FGF‑2 achieved a higher estrogen receptor‑α expression compared to the 2 ng̸ml FGF‑2‑only group. Within the limits of this study, simvastatin enhanced osteoblast differentiation. However, the combined treatment with simvastatin and FGF‑2 did not exert synergistic effects on osteoblast differentiation under the current experimental conditions. Future studies are required to evaluate divergent conditions and determine the selective timing and optimal dosage for the delivery of the agents.
View References
|
1
|
Park JB: The use of simvastatin in bone
regeneration. Med Oral Patol Oral Cir Bucal. 14:e485–e488.
2009.PubMed/NCBI
|
|
2
|
Mundy G, Garrett R, Harris S, et al:
Stimulation of bone formation in vitro and in rodents by statins.
Science. 286:1946–1949. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Biver E, Soubrier AS, Thouverey C, et al:
Fibroblast growth factor 2 inhibits up-regulation of bone
morphogenic proteins and their receptors during osteoblastic
differentiation of human mesenchymal stem cells. Biochem Biophys
Res Commun. 427:737–742. 2012. View Article : Google Scholar
|
|
4
|
Zhou L and Ogata Y: Transcriptional
regulation of the human bone sialoprotein gene by fibroblast growth
factor 2. J Oral Sci. 55:63–70. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Park JB: Effects of fibroblast growth
factor 2 on osteoblastic proliferation and differentiation by
regulating bone morphogenetic protein receptor expression. J
Craniofac Surg. 22:1880–1882. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Song T, Wang W, Xu J, et al: Fibroblast
growth factor 2 inhibits bone morphogenetic protein 9-induced
osteogenic differentiation of mesenchymal stem cells by repressing
Smads signaling and subsequently reducing Smads dependent
up-regulation of ALK1 and ALK2. Int J Biochem Cell Biol.
45:1639–1646. 2013. View Article : Google Scholar
|
|
7
|
Park JB: Low dose of doxycyline promotes
early differentiation of preosteoblasts by partially regulating the
expression of estrogen receptors. J Surg Res. 178:737–742. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Park JB: The effects of dexamethasone,
ascorbic acid, and β-glycerophosphate on osteoblastic
differentiation by regulating estrogen receptor and osteopontin
expression. J Surg Res. 173:99–104. 2012.
|
|
9
|
Park JB: Combination of simvastatin and
bone morphogenetic protein-2 enhances differentiation of
osteoblastic cells by regulating the expression of
phospho-Smad1/5/8. Exp Ther Med. 4:303–306. 2012.PubMed/NCBI
|
|
10
|
Park JB: Effects of doxycycline,
minocycline, and tetracycline on cell proliferation,
differentiation, and protein expression in osteoprecursor cells. J
Craniofac Surg. 22:1839–1842. 2011. View Article : Google Scholar
|
|
11
|
Park JB, Zhang H, Lin CY, et al:
Simvastatin maintains osteoblastic viability while promoting
differentiation by partially regulating the expressions of estrogen
receptors α. J Surg Res. 174:278–283. 2012.PubMed/NCBI
|
|
12
|
Pinzone JJ, Stevenson H, Strobl JS and
Berg PE: Molecular and cellular determinants of estrogen receptor α
expression. Mol Cell Biol. 24:4605–4612. 2004.
|
|
13
|
Kim CH, Cheng SL and Kim GS: Effects of
dexamethasone on proliferation, activity, and cytokine secretion of
normal human bone marrow stromal cells: possible mechanisms of
glucocorticoid-induced bone loss. J Endocrinol. 162:371–379. 1999.
View Article : Google Scholar
|
|
14
|
Ishida Y and Heersche JN:
Glucocorticoid-induced osteoporosis: both in vivo and in vitro
concentrations of glucocorticoids higher than physiological levels
attenuate osteoblast differentiation. J Bone Miner Res.
13:1822–1826. 1998. View Article : Google Scholar
|
